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Abstract
Introduction—Alpha-1-adrenergic receptors (α1-ARs) are G-protein coupled receptors (GPCRs) 
with three highly homologous subtypes (α1A, α1B, and α1D). Of these three subtypes, only the 
α1A and α1B are expressed in the heart. Multiple pre-clinical models of heart injury demonstrate 
cardioprotective roles for the α1A. Non-selective α1-AR activation promotes glycolysis in the 
heart, but the functional α1-AR subtype and broader metabolic effects have not been studied.
Objectives—Given the high metabolic demands of the heart and previous evidence indicating 
benefit from α1A activation, we chose to investigate the effects of α1A activation on the cardiac 
metabolome in vivo.
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Methods—Mice were treated for one week with a low, subpressor dose of A61603, a highly 
selective and potent α1A agonist. Cardiac tissue and serum were analyzed using a non-targeted 
metabolomics approach.
Results—We identified previously unrecognized metabolic responses to α1A activation, most 
notably broad reduction in the abundance of polyunsaturated fatty acids (PUFAs) and 
endocannabinoids (ECs).
Conclusion—Given the well characterized roles of PUFAs and ECs in inflammatory pathways, 
these findings suggest a possible role for cardiac α1A-ARs in the regulation of inflammation and 
may offer novel insight into the mechanisms underlying the cardioprotective benefit of selective 
pharmacologic α1A activation.
Keywords
alpha-1A adrenergic receptor; agonist; endocannabinoid; arachidonic acid; fatty acid elongation; 
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Introduction
Adrenergic receptors (ARs) are G-protein coupled receptors (GPCRs) that are activated 
endogenously by catecholamines and play critical roles in regulating cardiac function. The 
β1-AR is the most abundant AR in the heart and chronic activation of β1-ARs by 
catecholamines contributes to the pathobiology of heart failure. α1-ARs are less abundant, 
but play adaptive and protective roles in the heart, including induction of physiological 
cardiac hypertrophy, enhanced cardiac contractility, and protection against multiple forms of 
cardiac injury.1
Pharmacologic approaches have been used for decades to elucidate downstream effects of 
non-selective cardiac α1-AR activation. The endogenous catecholamines norepinephrine 
and epinephrine activate α1-ARs as well as β-ARs, whereas the synthetic drug 
phenylephrine is a non-selective α1-AR agonist used widely in experimental settings. 
Studies using these agents have identified important roles for α1-ARs in regulation of 
glucose metabolism in skeletal muscle 2, liver 3, pancreas4, and adipocytes5. Non-selective 
α1-AR activation in the heart increases glucose metabolism6,7 and decreases fatty acid 
oxidation.8 This metabolic substrate switch from fatty acid to glucose is a critical component 
of the heart’s adaptation to stress9,10. Despite the central role of catecholamines in cardiac 
biology, very little is known about their global metabolic effects in the heart. One previous 
study investigated the effects of β-AR stimulation on the rat cardiac metabolome11, but the 
broad metabolic effects of α1-AR stimulation have not been investigated.
There are three highly homologous subtypes of α1-ARs: α1A, α1B, and α1D, with variable 
tissue expression throughout the body. The α1A and α1B are expressed in the rodent and 
human heart, whereas the α1D is found in the coronary vasculature and mediates 
vasoconstriction12,13. Transgenic mouse models and pharmacologic approaches have begun 
to delineate distinct roles for the cardiac α1-AR subtypes, indicating that the α1A is 
cytoprotective in vitro and cardioprotective in vivo14. Transgenic mice overexpressing the 
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α1A in cardiomyocytes demonstrate enhanced contractility and functional recovery after 
ischemic challenge and pressure overload.15-17
Recent studies have expanded these observations using the potent and highly selective α1A 
agonist, A61603 (N-[5-(4,5-dihydro-1H-imidazol-2yl)-2-hydroxy-5,6,7,8-tetrahydro 
naphthalen-1-yl] methanesulfonamide hydrobromide)18 in multiple pre-clinical studies19-21. 
A61603 protects against cardiomyocyte death due to multiple cytotoxic exposures in vitro22, 
prevents doxorubicin-induced cardiotoxicity in vivo23, and restores right ventricular 
contractility in a mouse model of right heart failure19. Importantly, these beneficial effects 
were achieved using a dose of A61603 that did not increase blood pressure, suggesting that 
vascular α1-ARs were not activated, and reinforcing the possibility that selective α1A-AR 
activation might represent a novel approach to treating heart muscle disease24. It is unknown 
whether metabolic alterations contribute to these beneficial effects.
In the present study, mice were treated with A61603 then heart tissue and serum were 
analyzed using a non-targeted metabolomics approach to discover whether broad metabolic 
adaptations may underlie the cardioprotective effects of activating the α1A-AR in vivo.
Materials and Methods
Animals, experimental design, drug delivery, and harvest
Mice were 12-week old C57Bl6J males. All mice underwent implantation of subcutaneous 
osmotic minipump (Alzet) that delivered A61603 10ng/kg/d to 8 mice and vehicle (100μM 
vitamin C, 0.9% NaCl) to 8 mice for one week. Mice were fed the usual animal care diet per 
the San Francisco VA Animal Care facility. Mice were sacrificed under deep isoflurane 
anesthesia, blood was collected by cardiac puncture, clotted, and 100-200μL serum was snap 
frozen in liquid nitrogen. The heart was dissected, the atria and great vessels were excised, 
and the ventricles were allowed to beat in cold PBS to clear blood. Excess liquid was blotted 
then the heart was snap-frozen in liquid nitrogen and shipped to Metabolon (Durham, NC).
Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectroscopy (UPLC-
MS/MS)
All methods utilized a Waters ACQUITY ultra-performance liquid chromatography (UPLC) 
and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced 
with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated 
at 35,000 mass resolution. Samples were processed as previously described25,26, sample 
extract reconstituted in solvents containing a series of standards at fixed concentrations to 
ensure injection and chromatographic consistency. One aliquot was analyzed using acidic 
positive ion conditions, chromatographically optimized for more hydrophilic compounds. 
The extract was gradient eluted from a C18 column (Waters UPLC BEH C18-2.1x100 mm, 
1.7 μm) using water and methanol, containing 0.05% perfluoropentanoic acid (PFPA) and 
0.1% formic acid (FA). Another aliquot was also analyzed using acidic positive ion 
conditions, however it was chromatographically optimized for more hydrophobic 
compounds. In this method, the extract was gradient eluted from the same C18 column using 
methanol, acetonitrile, water, 0.05% PFPA and 0.01% FA and was operated at an overall 
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higher organic content. Another aliquot was analyzed using basic negative ion optimized 
conditions using a separate dedicated C18 column. The basic extracts were gradient eluted 
from the column using methanol and water, however with 6.5 mM Ammonium Bicarbonate 
at pH 8. The fourth aliquot was analyzed via negative ionization following elution from a 
HILIC column (Waters UPLC BEH amide 2.1x150 mm, 1.7 μm) using a gradient consisting 
of water and acetonitrile with 10mM ammonium formate, pH 10.8. The MS analysis 
alternated between MS and data-dependent MSn scans using dynamic exclusion. The scan 
range varied slightly between methods but covered 70-1000 m/z.
Raw data were extracted, peak-identified by comparison to library entries of purified 
standards or recurrent unknown entities based on authenticated standards that contain the 
retention time/index (RI), mass to charge ratio (m/z), and chromatographic data (including 
MS/MS spectral data). Biochemical identifications are based on retention index within a 
narrow RI window of the proposed identification, accurate mass match to the library +/- 10 
ppm, and the MS/MS forward and reverse scores between the experimental data and 
authentic standards. The MS/MS scores are based on a comparison of the ions present in the 
experimental spectrum to the ions present in the library spectrum. The QC and curation 
processes were designed to ensure accurate and consistent identification of true chemical 
entities, and to remove those representing system artifacts, misassignments, and background 
noise. Peaks were quantified using area-under-the-curve. For studies spanning multiple days, 
a data normalization step was performed to correct variation resulting from instrument inter-
day tuning differences. All data used in this analysis has been archived in the UCSD 
Metabolomics Workbench (http://www.metabolomicsworkbench.org/), accession # (Pending 
Assignment/Uploaded 17 April 2016).
Metabolomic Statistical Analyses
Metaboanalyst (v3.0) run on the statistical package R (v2.14.0) used metabolite peak areas 
(as representative of concentration)27,28. These data were first normalized to a pooled 
average sample from the relevant vehicle-treated group, and scaled using Pareto scaling 
feature. To detect systemic metabolic signature of A61603 treatment, a Pairwise One-Way 
Analysis of Variance (ANOVA) and Fisher LSD post-hoc test across the tissues (heart, 
serum) and experimental groups (vehicle treated, A61603-treated) were performed using 
Metaboanalyst v3.0. ANOVA significant metabolites (FDR<0.05) were matched to 
metabolomics pathways using the Pathway Analysis and enrichment analysis features in 
Metaboanalyst 3.0. Only metabolites identified and detected in all groups were included in 
the one-way ANOVA. Up to three missing values in each group were imputed. If four or 
more values of each metabolite were missing in a given group, the entire metabolite was 
removed from the analysis. Only metabolites significantly altered between tissue-matched 
control and A61603 treatment groups were included. All data from this study are available in 
Supplemental Table 1. Heat maps were generated using the GENE- E software (http://
www.broadinstitute.org/cancer/software/GENE-E/index.html) and Microsoft Excel 2016. 
All data are shown as mean ± SEM, unless otherwise indicated.
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Results
Heart Tissue
We compared heart tissue from mice treated for 7 days with the selective α1A-AR agonist, 
A61603, or vehicle. We used a very low A61603 dose, 10 ng/kg/d, that has no detectable 
effect on blood pressure, heart rate, heart size, or heart function, but does increase 
phosphorylation of cardiac ERK, a canonical α1A signaling partner. (data not shown) All 
comparisons used a one-way ANOVA to identify significantly altered metabolites. Of the 
503 total metabolites identified in heart, 381 were adequate for the one-way ANOVA 
(Supplemental Figures 1and 2), and 30 were ANOVA-significant with a false discovery rate 
(FDR) < 0.05 (Figure 1A). Metaboanalyst recognized 23 of these 30 metabolites and applied 
pathway analysis to identify biosynthesis of unsaturated fatty acids as the most affected 
pathway (Figure 1B, p=1.29E-11, FDR=1.06E-9). Metaboanalyst enrichment analysis for 
pathways identified alpha linoleic acid and linoleic acid metabolism, ammonia recycling, 
and urea cycle with the lowest p values, enriched 3 to10 fold (Figure 1C). Enrichment 
analysis for location identified the peroxisome with the lowest p values, enriched 1.5-2.0 
fold expected (data not shown).
Of the 7 metabolites not recognized by Metaboanalyst for pathway analysis using multiple 
synonymous chemical names (i.e. N-Palmitoyl taurine*, 1-(1-enyl-stearoyl)-GPE, 
Palmitoylethanolamide*, N-Stearoyltaurine*, Oleoyl Ethanolamide*, 1-palmitoyl GPG, 10-
Nonadecenoic acid, 15-Methylpalmitate), 4 are involved in the endocannabinoid (EC) 
Pathway. The EC system consists of cannabinoid receptors and their endogenous 
neuromodulatory lipid ligands that collectively play long-recognized roles in the 
neurological and immunological systems29 and recently have been identified in the heart30. 
We found a roughly 50% decrease in the abundance of the biologically active EC 
metabolites oleoyl ethanolamide, palmitoyl ethanolamide, N-stearoyltaurine, and N-
palmitoyltaurine after treatment with A61603 (Figure 2).
Review of specific metabolites within these pathways revealed a 25% decrease in cardiac 
arachidonic acid, an omega (ω)-6 polyunsaturated fatty acid (PUFA) (Figure 2 Figure 3B). 
Similarly, we found decreases of ~25-45% in eight metabolites involved in the synthesis of 
ω3 (Figure 3A) and ω6 fatty acids (Figure 3B). Biosynthesis of PUFAs, including 
arachidonic acid, occurs through multiple desaturation and elongation steps (Figures 3 and 
B), each controlled by distinct enzymes.31 Our findings suggest that activation of the α1A 
broadly reduces ω3 and ω6 fatty acid synthesis, possibly through regulation of one or more 
of these desaturates and elongases.
There was no clear signal that α1A activation affected glucose metabolism, though pyruvate 
levels were consistently and significantly decreased in hearts of A61603-treated mice 
(Figure 1A). Collectively, these findings suggest that A61603-treatment significantly affects 
the biosynthesis of biologically active PUFAs and EC receptor ligands.
Serum
Of the 543 total metabolites identified in serum, 381 were adequate for one-way ANOVA 
(Supplemental Figures 4 and 5), and 34 of them were ANOVA significant with an FDR < 
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0.05 (Figure 4A). Pathway analysis of these 34 metabolites identified pyrimidine 
metabolism as the most likely affected pathway (Figures 4B and 4C, p=0.026, FDR =1). The 
pyrimidine salvage pathway (Figure 5) recovers core pyrimidine components which are 
recycled for use as nucleic acids or for recovery of nitrogen to the general nitrogen 
metabolism32. Further analysis of metabolites in the pyrimidine salvage pathway revealed 
that A61603 treatment is associated with significant decreases in serum levels of 
deoxycytidine, deoxyuridine, and ureidopropionate (Figure 5). All three of these metabolites 
are intermediates in β-alanine synthesis, but A61603 treatment did not affect abundance of 
β-alanine in either serum or heart.
Of note, treatment with A61603 had no effect on serum glucose, cholesterol, or creatinine 
levels—three commonly used markers of cardiovascular risk in the clinical setting. 
Collectively, these findings suggest relatively minimal systemic effects from the 
administration of an α1A agonist.
Heart and Serum
We next determined if there were A61603-altered metabolites in the serum that might reflect 
A61603-altered metabolites in the heart and might serve as a circulating marker of cardiac 
response to A61603. Since there were no metabolites found in our initial stringent cut-off of 
an FDR<0.05, we decreased the stringency to FDR<0.10 and identified A61603-induced 
metabolites compared to the vehicle controls (Figure 6A). Only 5-hydroxy-lysine overlapped 
in both compartments (Figure 6A, top row).
Since both A61603-induced heart and serum 5-hydroxy-lysine levels were significantly 
different by FDR (defined as <0.10), we next compared these groups using one-way 
ANOVA (Figure 6B). There was a statistically significant change in A61603-treated heart 
compared to its vehicle control (p<0.02)(Figure 6B), and the A61603-treated serum had a p 
value trending to significance (p=0.128)(Figure 6B). 5-Hydroxylysine is a hydroxylated 
derivative of the amino acid lysine present in certain collagens and belongs to a class of 
organic compounds known as hydroxyl-fatty acids33. While the changes in the serum 
reflected those in the heart, a more sensitive marker or set of serologic markers would be 
needed to follow A61603 activity in the heart. As such, the metabolite subset recognized in 
the current study did not identify a reliable serum metabolite marker for the cardiac effects 
of A61603.
Discussion
In this study, we used non-targeted metabolomics analysis to identify previously 
unrecognized links between pharmacological α1A-AR activation and biosynthesis of PUFAs 
and ECs in the heart. These findings expand our limited understanding of adrenergic 
regulation of the cardiac metabolome and generate novel hypotheses regarding the activity 
of cardiac α1A-ARs. In particular, PUFAs and ECs both play central roles in inflammation, 
suggesting that regulation of inflammation may contribute to the demonstrated 
cardioprotective effects of the selective α1A agonist, A61603.
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We discovered that systemic treatment with A61603 broadly reduced the cardiac content of 
ω3, ω6, and ω9 PUFAs without affecting serum PUFA levels. PUFAs play critical and 
complex roles in the heart, acting act as both biosynthetic intermediates and signaling 
molecules34. Observational studies have linked higher serum ω3-PUFA levels and dietary 
PUFA intake with lower mortality due to cardiovascular disease35. However, the biological 
relevance of PUFA abundance in cardiac tissue is uncertain and rodent models have 
demonstrated that dietary PUFA content is not correlated with heart content36. Previous 
reports indicate that treatment with PUFAs leads to a decrease in α1-AR mediated 
contractility in cultured cardiomyocytes37,38, but the role of cardiac α1-ARs in regulating 
PUFA biosynthesis has not been explored.
We found decreases in ostensibly beneficial ω3 PUFAs such as docosapentanoic acid (DPA) 
and docosahexanoic acid (DHA)39, as well as more cardiotoxic PUFAs such as the ω9 
PUFA, erucic acid40,41. Arachidonic acid (AA), among the most extensively studied of 
PUFAs, was decreased to 0.74-fold relative abundance in the hearts of mice treated with 
A61603. Previous studies have reached variable conclusions about the function of AA in the 
heart, in part because AA metabolites play conflicting roles—some beneficial42 and some 
maladaptive43. AA is released from membrane phospholipids by phospholipases. α1-AR 
stimulation activates phospholipase C44 and phospholipase D45,46, which cleave 
phospholipids to diacyl glycerol (DAG) and phosphatidic acid respectively. These lipid 
products are then enzymatically converted to AA. In our study, A61603 treatment increased 
total DAG content by 24% (p<0.05). The observed decrease in AA content could potentially 
result from regulation of DAG lipase—the enzyme that converts DAG to AA--or through an 
increase in conversion of AA to downstream metabolites.
PUFAs have not been studied widely in injured heart tissue. PUFA abundance in the heart is 
not affected by activation of the angiotensin I receptor47, and treatment with the β-AR 
agonist isoproterenol increases AA 3.4-fold and the ω6 PUFA linoelaidic acid 2.5-fold11. 
Chronic activation of both the angiotensin I receptor and the β-AR lead to maladaptive 
cardiac hypertrophy and heart failure. Consistent with these findings, AA and DHA increase 
in failing human heart tissue as well as hypertrophied and failing rat hearts48. In contrast, 
sustained α1A activation leads to a decrease in PUFA levels and cardioprotection, though 
the mechanistic connection between these findings is uncertain. Collectively, these studies 
illustrate the complexity of ascribing inherent benefit or harm to tissue PUFA levels.
Our results also indicate that pharmacological activation of the α1A-AR leads to decreased 
levels of ECs in the heart. ECs are metabolites in the AA biosynthetic pathway, formed by 
activation of fatty acid amid hydrolase49. ECs participate in the regulation of cellular 
metabolism and inflammation through activation of CB1, CB2, and TRPV1 channels. The 
effects of ECs in the heart are either beneficial50 or maladaptive51,52, depending on context 
and selective receptor activation53.
Cardioprotective mechanisms induced by EC modulation include enhanced Na+/Ca2+ 
exchange current54, activation of HSP72, PKA, PLC, PKC, eNOS, iNOS, and ERK1/255-57, 
and regulation of myosin heavy chain isoform switching50. Interestingly, α1-AR activation 
regulates each of these processes in the heart as well, suggesting that the EC system may 
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participate broadly in the mechanisms underlying α1-mediated cardioprotection. Of 
particular significance to our current study, ECs have been shown to decrease responsiveness 
to AR agonist stimulation in the vasculature58,59, to mediate α1-induced glutamate 
neurotransmission in the central nervous system60, and to regulate peripheral norepinephrine 
release61. However, our study is the first to show an effect of α1-AR activation on EC 
biosynthesis.
Given the complex functions of both PUFAs and the EC system in the heart, it is unclear 
how our findings might help to explain the cardioprotective effects of A61603. However, one 
reasonable hypothesis is that α1A activation regulates inflammation, insofar as many of the 
metabolites that were reduced in A61603-treated hearts are involved in inflammatory 
pathways. ECs are well-recognized mediators of systemic inflammatory diseases such as 
rheumatoid arthritis61, and also regulate inflammation in the heart62. PUFAs regulate T 
lymphocyte function63 and modify inflammatory diseases64 and AA and its metabolites 
provide critical positive and negative regulation of systemic and cardiac inflammation65. 
Inflammation is central to the biology of acute myocardial injury69 and to the 
pathophysiology of chronic heart failure70 and α1A activation is protective in both settings. 
The role of inflammation in the heart is complex, however, and inflammatory mediators 
released from both circulating cells or any of the resident cell cardiac types play both 
adaptive and maladaptive roles.
The role of α1-ARs in regulating cardiac inflammation has not been explored to any 
significant extent. Transgenic mice overexpressing a constitutively active α1A have 
increased IL-6 expression in the heart, but no evidence of increased cardiac inflammation66. 
These mice are protected against ischemia-reperfusion injury, a condition that typically is 
worsened by inflammation. One other study found that non-selective α1-AR activation 
suppresses lipopolysaccharide-induced cardiomyocyte TNF-α expression and improves 
cardiac dysfunction during endotoxemia through ERK activation and NF-κB suppression67. 
α1-ARs are found on monocytes and macrophages, and their activation appears to alter 
production of inflammatory mediators68. Our analysis of the serum of mice treated with 
A61603 revealed no clear evidence of systemic inflammatory modulation, though reduction 
in pyrimidine salvage intermediates (Figure 5), would favor a reduction in inflammatory cell 
function.69,70 The role of the α1A-AR in regulating cardiac inflammation will be the subject 
of future work in our lab.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Non-standard abbreviations
A61603 alpha-1 adrenergic receptor agonist: N-[5-(4,5-dihydro-1H-imidazol-2yl)-2-
hydroxy-5,6,7,8-tetrahydro naphthalen-1-yl] methanesulfonamide 
hydrobromide
α1-AR alpha1-adrenergic receptor
AA arachidonic acid
CB1/2 cannabinoid receptor type 1/2
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DAG diacylglycerol
DHA docosahexaenoic acid
DPA docosapentaenoic acid
ECs endocannabinoids
GPCR G-protein coupled receptor
PUFA poly-unsaturated fatty acid
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Figure 1. Analysis of non-targeted metabolomics of hearts from vehicle-treated and A61603-
treated mice
A. Summary heat map of pairwise One-way ANOVA significant metabolites, determined by 
Fisher-LSD post hoc test results. Fisher LSD post hoc comparisons were made between 
A61603-treated and vehicle-treated heart groups (N=8/group). B. Pathway enrichment 
analysis for A61603–treated heart group compared to vehicle-treated heart group, 
determined by ANOVA significant metabolites in the heart. a-c indicates top pathways 
identified C. Enrichment analysis of cardiac A61603-mediated alterations compared to 
pathway metabolite sets
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Figure 2. Functional annotation of A61603-mediated alterations in cardiac metabolites in vivo
Overview of the endocannabinoid pathway and the intermediates altered in vivo by A61603 
treatment, determined by One-way ANOVA test results in the heart (p<0.05). Data represent 
mean ± SEM. (N=8/group). *p<0.05.
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Figure 3. Functional annotation of N-3 and N-6 unsaturated fatty acid biosynthesis including 
intermediates altered in heart tissue by in vivo A61603
α1A-mediated alterations in A. N-3 poly-unsaturated fatty acids (PUFAs) and B. N-6 poly-
unsaturated fatty acids (PUFAs) in the heart, determined by One-way ANOVA (p<0.05). ∆ 
(delta) references the specific double bonds present in fatty acids. Data represent mean ± 
SEM. (N=8/group). *p<0.05.
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Figure 4. Analysis of non-targeted metabolomics of serum from vehicle-treated and A61603-
treated mice
A. Summary heat map of pairwise One-way ANOVA significant metabolites, determined by 
Fisher-LSD post hoc test results (significance defined as FDR<0.05). Fisher LSD post hoc 
comparisons were made between A61603-treated and vehicle-treated serum groups (N=8/
group). Only significantly altered metabolites are shown. Significance was defined as FDR 
<0.05. B. Pathway enrichment analysis for A61603-treated serum group compared to 
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vehicle-treated serum group. a-c indicates top pathways identified. C. Enrichment analysis 
of A61603-mediated alterations in serum compared to pathway metabolite sets.
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Figure 5. Functional annotation of A61603-mediated alterations in serum intermediates from the 
pyrimidine salvage pathway
Overview of the pyrimidine salvage pathway and the serum intermediates altered in vivo by 
A61603 treatment, determined by One-way ANOVA. Data are shown as mean ± SEM. 
(N=8/group)
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Figure 6. A61603 responsive metabolite found in heart and plasma
Metabolites significantly altered by A61603 in A. Heart and serum. A pairwise One-way 
ANOVA was performed to identify significant metabolites using a Fisher-LSD post-hoc test 
results against either vehicle-treated heart (left column) or vehicle-treated serum (right 
column), which included those identified in Figure 1A (heart) or Figure 4A (serum), using a 
slightly lower stringency (significance defined as FDR<0.10) to identify metabolites altered 
in both. Data represent mean ± SEM. (N=8/group). *FDR<0.10, #p<0.02.
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